Official information on December 10: Qihao Medical announced today that it has completed tens of millions of yuan in Series A financing. The investors are led by the Hefei Industrial Investment Promotion Venture Capital Fund, Hefei Angel Investment Fund, Anhui Huaying Smart IoT Fund, etc. Follow-up investment is complete Develop innovative drugs for patients with central nervous system diseases　

　 Qihao Medical is a company that develops medical devices in the field of ENT. It is committed to the development of advanced consumables and equipment, and provides overall solutions for ear, nose and throat surgery. It has two core products: "Low-temperature plasma radio frequency surgery system" and "Fully degradable sinus drug stents."　 Established in 2017, Qihao Medical, after three years of design, research and development, and testing and production, has obtained a second-class certificate product, and it has been sold nationwide. Two third-class products are currently undergoing clinical trials in 7 domestic hospitals, and the progress is smooth. It is worth mentioning that the degradable (expandable) hemostatic cotton created by the R&D team is currently the first domestically produced. Previously, only one medical device company in the United States developed a absorbent cotton to stop bleeding in the ear, nose and throat. Qihao Medical has broken this market monopoly, and will soon begin to expand production at the Hefei factory, realizing a new situation of domestic substitution.　　 It is understood that under the guidance and advice of well-known domestic ENT experts such as Peking University People’s Hospital, Guangzhou Zhongshan First Hospital, Shanghai Sixth Hospital, Qihao Medical’s next round of R&D plans for four new ENT products has been launched. Achieving innovative breakthroughs in technology, with the strong encouragement and help of the company's chief scientist "Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences", deputy director Zhou Feng, and co-founded the Zhongke Qihao Biomedical Materials Joint Laboratory in the Lanzhou Institute of Chemical Technology. What is the next step of Qihao Medical?　　　　

　　 Mr. Pang Yonggang, the founder of Qihao Medical, said that after this round of financing, the company’s future development headquarters, Hefei Qihao Medical Technology Co., Ltd., will be formally established. At the same time, the team also plans to build a 1,000-square-meter clean production workshop in Hefei. It is used in production pilot products such as nasal sinus balloon and biodegradable (expandable) hemostatic cotton. What is the reason for the investor's investment in this round?　　 The lead investor, Hefei Investment Promotion Fund, pointed out that medical health has always been one of the key industries in Hefei. Hefei Investment Promotion Fund invests in Qihao Medical. The first is to value the promising market of ENT medical equipment in the future. The second is to take a fancy to the continuous R&D capabilities and innovation capabilities of the technical team. The third is that the prototype of the company's entire product line has matured, and the product portfolio system is also sound. The fourth is the deep industry accumulation of the institution's trust in Dr. Pang and his team. Through the combination of investment promotion funds and angel funds, Hefei Industrial Investment Group will guide Qihao Medical to accelerate the development. How does SynTao Venture Capital.com comment on this financing event? According to Wang Shuai, founder of SynTao Ventures, the number of patients in the domestic otolaryngology department is increasing every year, and the corresponding medical resources are relatively scarce. Qihao Medical is committed to developing a full range of products for the ENT department and realizing domestic substitution. Greatly increase the opportunities for medical informatization in related fields. It is hoped that the company can provide better overall solutions in the future to benefit more patients.